A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q35678690

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@ast

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@en

type

Item

label

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@ast

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@en

prefLabel

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@ast

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@en

P1476

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

@en

P2093

H Kawakami

http://www.w3.org/2001/XMLSchema#string

J Tsurutani

http://www.w3.org/2001/XMLSchema#string

K Nakagawa

http://www.w3.org/2001/XMLSchema#string

K Nishio

http://www.w3.org/2001/XMLSchema#string

K Tanaka

http://www.w3.org/2001/XMLSchema#string

T Iwasa

http://www.w3.org/2001/XMLSchema#string

T Kurata

http://www.w3.org/2001/XMLSchema#string

T Sakiyama

http://www.w3.org/2001/XMLSchema#string

T Yoshida

http://www.w3.org/2001/XMLSchema#string

Y Fujisaka

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A

P2888

bjc.2015.10

P304

819-824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2015.10

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272079736

http://www.w3.org/2001/XMLSchema#string

P6179

1043405335

http://www.w3.org/2001/XMLSchema#string

P698

25654665

http://www.w3.org/2001/XMLSchema#string

P932

4453950

http://www.w3.org/2001/XMLSchema#string